Loading clinical trials...

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery. | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGPHASE3

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

NCT07357675•EBI Anti Sepsis BV

View on ClinicalTrials.gov

Summary

EA-230 is a new therapy that may help people recover faster and have fewer problems after bypass surgery. In an earlier clinical trial, participants who received EA-230 during Coronary Artery Bypass surgery stayed in the Intensive Care Unit (ICU) and the hospital for a shorter time and had fewer serious complications, compared to those who received a placebo (an inactive therapy). The use of EA-230 was safe and well tolerated. This trial will test EA-230 in more participants to see if it really works and is safe to use in the future. This is a Phase III trial. It will take place in multiple locations and will follow a double-blind, randomized, placebo-controlled clinical design, meaning neither doctors nor participants will know whether they receive EA-230 or placebo during the trial. Assignment to EA-230 or placebo occurs by chance, like throwing dice. The total duration of the trial, including medical check-ups, will be approximately 71 days. There is a total of 10 visits, including a screening-, a pre-operative-, and 2 remote visits. 7 of these visits are during your stay at the hospital.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Patients aged ≥18 years, both male and female.
•2. Patients scheduled for elective on-pump CABG with at least 3 bypasses, with or without valve replacement.
•3. For women of childbearing potential (WOCBP), agree to use adequate contraception17 from enrollment and up to 28 days after IMP administration, and must have a negative pregnancy test prior to entry into the trial.
•4. For male patients, agree to use adequate contraception and refrain from donating sperm from enrollment and up to 28 days after IMP administration.
•5. Willing and able to give written informed consent.

Exclusion Criteria

•1. Patients undergoing non-elective on-pump CABG (i.e., emergency surgery). Emergency surgery is defined as planned surgery within 24 hours of diagnosis.
•2. Cardiogenic shock or hemodynamic instability that requires inotropes, vasopressors, or other mechanical devices, such as an intra-aortic balloon counter-pulsation (IABP), within 24 hours prior to surgery.
•3. Use of a left ventricular assist device (LVAD), or intra-aortic balloon pump or other cardiac devices, within 7 days prior to surgery.
•4. A requirement for any of the following within 7 days prior to surgery: defibrillator or permanent pacemaker, mechanical ventilation, IABP, LVAD, or other forms of mechanical circulatory support.
•5. Required cardiopulmonary resuscitation within 14 days prior to cardiac surgery.
•6. Known chronic liver disorder with Child-Pugh C classification.
•7. Confirmed or treated endocarditis requiring antimicrobial or antiviral treatment within 30 days prior to surgery or other current active infection requiring antimicrobial or antiviral treatment within 14 days prior to surgery.
•8. Ongoing sepsis (as defined by SEPSIS-3) within 2 weeks of screening or, in the opinion of the investigator, an untreated clinically significant infection (viral or bacterial) prior to or at Screening and before randomization.
•9. Immuno-compromised patients, as self-reported or as observed in medical records, including patients:
•1. with solid organ transplantation.
+16 more criteria

Locations (5)

MAYO clinic

Rochester, Minnesota, United States

UZ Gent

Ghent, Belgium

Medisch Spectrum Twente

Enschede, Netherlands

RadboudUMC

Nijmegen, Netherlands

St Thomas' Hospital

London, United Kingdom

Key Dates

Start Date

April 1, 2026

Primary Completion Date

March 24, 2027

Completion Date

May 1, 2027

Last Updated

January 22, 2026

Enrollment

300

ESTIMATED participants

Conditions

Coronary Artery Disease (CAD)Coronary Artery Bypass Graft Surgery(CABG)

Interventions

EA-230 90mg/kg/hour

DRUG

Placebo

DRUG

Contacts

Bas Ossenkoppele, Msc

CONTACT

+31 620033017 bas.ossenkoppele@cr2o.nl

Leonie Koomen, Msc

CONTACT

+31610518323 leonie.koomen@cr2o.nl

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Dedinje FFR/QFR Registry

NCT06659367

Coronary Artery Disease (CAD)Fractional Flow Reserve

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 22, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Clinical Trial To Investigate The Effect Of EA-230 On Hospital Length Of Stay In Patients With Coronary Artery Disease (CAD) Undergoing Coronary Artery Bypass Grafting (CABG) Surgery.

Inclusion Criteria

Exclusion Criteria

"Erectile Function After PCI in MI and Non-MI Patients"

Dedinje FFR/QFR Registry

Hemodynamic Parameters in People With Atherosclerotic Vascular Disease Referred to a Secondary Prevention and Cardiovascular Rehabilitation Program

Predictors and Long-term Incidence of In-stent Restenosis After Chronic Total Occlusion Percutaneous Coronary Intervention

Safety and Efficacy of De-escalation Dual Antiplatelet Therapy After BioFreedom™ Stenting in ACS Patients With Moderate-to-high Ischemic and High Bleeding Risk

Effect of a Low Advanced Glycation End Products Diet of Patients With Type 2 Diabetes Mellitus